autoimmune disease
| 4 min read
FDA guidance now limits routine tissue biopsies, forcing researchers to rethink how blood biopsies can be optimized to reveal tissue biology.
| 6 min read
A clinical trial showed that Rhapsido can safely and effectively treat chronic spontaneous urticaria; its developer Novartis hopes that’s just the start.
| 8 min read
By starting with T cells from healthy donors, Allogene is manufacturing off-the-shelf CAR T cell therapies that patients don’t have to wait for.
| 4 min read
A novel immunotherapy targets the liver to promote tolerance to allergens in mice, promising durable allergy relief without the risk of severe reactions.
| 8 min read
A new approach for gene editing will get its shot in a common and chronic autoimmune disorder.
| 4 min read
As a CD40 ligand antagonist, dazodalibep blocks immune cell communication, potentially serving as the first drug to target the autoimmune disease’s cause.
| 4 min read
Industry leaders name the clinical trials and developments they’re most excited to see in the new year.
| 4 min read
Bristol Myers Squibb unveiled promising CAR T cell therapy data for severe autoimmune diseases from their Phase 1 clinical trial, offering hope for remission.
| 4 min read
Novartis’ iscalimab may improve troubling symptoms in patients with Sjögren’s disease, though there may be safety concerns to address.
| 10 min read
Exhilarated but cautious, researchers are eager to see if CAR T cell therapy offers a one-time treatment for lupus.
